arrow
H

Henrik Lindman

bahcesehir university
H指数:39
被引数:5,394

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A human pan-disease blood atlas of the circulating proteome

循环蛋白质组的人类泛疾病血液图谱

SCIENCE
IF45.8
2025-12-183
PRE
Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients
2024-10-211
OAAI
Effects of heavy-load strength training during (neo-)adjuvant chemotherapy on muscle strength, muscle fiber size, myonuclei, and satellite cells in women with breast cancer
2024-07-023
PRE
The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial
2024-01-041
OAAI
Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR plus ), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project
2023-10-264
OAAI
Current treatment landscape of HR+/HER2− advanced breast cancer in the Nordics: a modified Delphi study

HR+/HER2−晚期乳腺癌在北欧地区的当前治疗格局:一项改良德尔菲研究

2023-09-150
PRE
Next generation pan-cancer blood proteome profiling using proximity extension assay
2023-07-1811
OAAI
Human Epidermal Growth Factor Receptor 2-Targeting [68Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer

靶向人表皮生长因子受体2 [68Ga]Ga-ABY-025 PET/CT预测转移性乳腺癌的早期代谢反应

2023-07-1317
OAAI
Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer
2023-04-1815
OAAI
Correlative and longitudinal transcriptomic profiling predicts patient outcomes and the efficacy of neoadjuvant HER2-targeted treatments in the randomized PREDIX HER2 trial
2023-03-010
PRE